SENESCO SIGNS PACT FOR UP TO $1.0 MILLION IN FINANCING.

Senesco Technologies, Inc. (NYSE Amex: SNT), New Brunswick, N.J., has announced that the company entered into a definitive purchase agreement with Partlet Holdings Ltd. for the issuance and sale of (i) up to 1,111,111 shares of its common stock (the "Shares") at a price of $0.90 per share, (ii) warrants to purchase an aggregate of up to 1,000,000 shares of common stock, which warrants are exercisable immediately at an exercise price of $0.01 per share (the "Partlet Series A Warrants") and (iii) warrants to purchase an aggregate of up to 2,055,555 shares of common stock, which warrants are exercisable 6 months from the date of issuance at an exercise price of $0.60 per share (the "Partlet Series B Warrants"). In connection with the private placement, the company anticipates that it will receive aggregate proceeds in the amount of $1,000,000.

On July 9, 2009, the company closed on $950,000 of aggregate proceeds of the private placement and, on that date, issued (i) a total of 1,055,555 shares (ii) a Partlet Series A Warrant to purchase 950,000 shares of the company's common stock and (iii) a Partlet Series B Warrant to purchase 1,952,778 shares of the company's common stock. The remaining $50,000 in proceeds cannot be closed upon until the company receives stockholder approval for certain aspects of the transaction. Assuming all of the proceeds of the private placement can be closed upon, the company anticipates it will receive gross proceeds equal to $1,000,000.

There are no registration rights associated with the securities sold in the private placement and no placement agent was used in connection with the private placement.

Senesco primarily intends to utilize the proceeds of this private placement as an initial step to help advance its research in multiple myeloma with the goal of initiating a Phase I clinical trial.

"We are pleased to have raised this additional capital," commented Joel Brooks, chief financial officer. "This funding allows us to remain focused on our goal of filing an Investigational New Drug Application and initiating a Phase I clinical trial for SNS-01."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

For more information, http://www.senesco.com or call 212/850-5600.

Print Get the Mag Weekly Updates